Drug Profile
MGAWN1
Alternative Names: hE16; MGAWN 1; West Nile virus monoclonal antibody - MacroGenicsLatest Information Update: 03 Dec 2012
Price :
$50
*
At a glance
- Originator Washington University
- Developer MacroGenics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued West Nile virus infections
Most Recent Events
- 06 Nov 2012 Discontinued - Phase-II for West Nile virus infections in Canada (IV)
- 06 Nov 2012 Discontinued - Phase-II for West Nile virus infections in USA (IV)
- 01 Nov 2010 MacroGenics completes enrolment in a phase II trial in West Nile virus infections in USA